drugset
drugset / Trial / NCT04174898

MSC Infusion for Anti-aging and Regenerative Therapy

NCT04174898 ↗

Phase 1 Unknown 100 enrolled Landmark Medical Centre Sdn Bhd CytoMed Therapeutics Pte Ltd · collab
NaSingle-groupOpen-labelPrevention

Summary

To evaluate the safety and efficacy of human Mesenchymal Stem Cell (hMSC) infusion therapy, in preserving general wellness and ameliorating or reversing the effects of aging in our study population

Timeline

Start
2020-04-15
Primary completion
2021-04-14
Completion
2022-04-14

Drugs

EvaluationDrugModalityDoseRoute
Subject human Mesenchymal Stem Cell (MSC) Cell therapy 100 cells Intravenous

Indications

No indication recorded.